We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sinopharm’s COVID-19 vaccine generated antibodies at levels on par with some of its competitors, according to early trial data released by scientists connected with the company and other China-based research institutes. Read More
A potential COVID-19 treatment that uses mesenchymal stem cells (MSCs) has flown under the radar thus far, but the therapy has shown promise in early research, and phase 2/3 results that will likely come out in early fall could show that it’s a game changer. Read More
The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) is developing a weakened strain of SARS-CoV-2 for use in human challenge trials in case they’re needed to fully evaluate COVID-19 vaccine and therapeutic candidates, though the institute says the controversial studies would not replace phase 3 trials. Read More
The FDA expects sponsors of breast cancer trials to include men as well as women and the scarcity of men with the condition is not an acceptable reason for excluding them from a trial, according to a new final guidance from the FDA. Read More
Mexico’s drug regulators have approved RedHill Biopharma’s planned phase 2/3 trial of Yeliva (opaganib) in hospitalized COVID-19 patients with pneumonia. Read More
Vir Biotechnology plans to launch a phase 2/3 trial this month of VIR-7831, a neutralizing monoclonal antibody for the treatment of COVID-19 patients. Read More
Mexico has agreed to host several phase 3 clinical trials of potential COVID-19 vaccines as the pace of research worldwide continues to gain momentum. Read More
Russia has approved the world’s first coronavirus vaccine, President Vladimir Putin announced Tuesday, prompting widespread concerns about the vaccine’s safety as it is only entering a late-stage clinical trial this week. Read More